PASSIGLIA, Francesco
 Distribuzione geografica
Continente #
NA - Nord America 2.239
EU - Europa 1.141
AS - Asia 954
OC - Oceania 50
SA - Sud America 39
AF - Africa 33
Continente sconosciuto - Info sul continente non disponibili 3
Totale 4.459
Nazione #
US - Stati Uniti d'America 2.175
CN - Cina 496
IT - Italia 453
FR - Francia 137
GB - Regno Unito 96
DE - Germania 86
JP - Giappone 82
VN - Vietnam 71
IN - India 66
CA - Canada 55
NL - Olanda 54
AU - Australia 47
SE - Svezia 39
KR - Corea 38
TW - Taiwan 38
PL - Polonia 35
HK - Hong Kong 34
RU - Federazione Russa 30
BE - Belgio 28
CZ - Repubblica Ceca 23
PH - Filippine 23
CH - Svizzera 20
ES - Italia 20
ZA - Sudafrica 17
UA - Ucraina 16
ID - Indonesia 15
IR - Iran 15
MK - Macedonia 15
RO - Romania 15
TR - Turchia 15
CL - Cile 14
IE - Irlanda 13
UZ - Uzbekistan 12
DK - Danimarca 11
FI - Finlandia 11
GR - Grecia 10
BR - Brasile 9
MX - Messico 8
SG - Singapore 8
JO - Giordania 7
MY - Malesia 7
PT - Portogallo 7
AR - Argentina 6
IL - Israele 6
NG - Nigeria 6
AT - Austria 5
CO - Colombia 5
SA - Arabia Saudita 5
HU - Ungheria 4
MA - Marocco 4
PE - Perù 4
SI - Slovenia 4
HR - Croazia 3
NZ - Nuova Zelanda 3
PK - Pakistan 3
AE - Emirati Arabi Uniti 2
AP - ???statistics.table.value.countryCode.AP??? 2
EG - Egitto 2
KH - Cambogia 2
LB - Libano 2
NO - Norvegia 2
RS - Serbia 2
TH - Thailandia 2
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BT - Bhutan 1
CI - Costa d'Avorio 1
DJ - Gibuti 1
EU - Europa 1
MO - Macao, regione amministrativa speciale della Cina 1
MZ - Mozambico 1
PR - Porto Rico 1
PS - Palestinian Territory 1
TN - Tunisia 1
Totale 4.459
Città #
Fairfield 252
Ashburn 177
Santa Cruz 170
Seattle 146
Buffalo 108
Torino 104
Woodbridge 95
Houston 90
Wilmington 71
Cambridge 68
Ann Arbor 67
Beijing 56
Dong Ket 56
Turin 55
Shanghai 53
Nanjing 42
San Diego 34
New York 33
Chicago 32
Guangzhou 32
Pisa 31
Stockholm 31
Tokyo 30
Taipei 28
Warsaw 28
Amsterdam 24
Changsha 23
Mountain View 23
Fleming Island 22
Las Vegas 22
Los Angeles 22
Wuhan 21
Verona 19
Clearwater 18
Hangzhou 16
Jinan 16
Chengdu 15
Shenyang 15
Chongqing 14
Bengaluru 13
Brooklyn 13
Milan 13
Muizenberg 13
Ottawa 13
Bukhara 12
Henderson 12
Berlin 11
Rome 11
London 10
Seoul 10
Utrecht 10
Duncan 9
Florence 9
Melbourne 9
Nanning 9
Skopje 9
Toronto 9
Atlanta 8
Changchun 8
Dublin 8
Helsinki 8
Lake Forest 8
Paris 8
Piemonte 8
Winnipeg 8
Zhengzhou 8
Central District 7
Dearborn 7
Frankfurt am Main 7
Hefei 7
Pittsburgh 7
Provo 7
San Jose 7
Brisbane 6
Jakarta 6
Madrid 6
San Giorgio Piacentino 6
Xian 6
Bethnal Green 5
Biella 5
Boardman 5
Dehra Dun 5
Hanoi 5
Kings Lynn 5
Munro 5
Osaka 5
Philadelphia 5
Saint Louis 5
Shenzhen 5
Tianjin 5
Alessandria 4
Amman 4
Ankara 4
Brookline 4
Central 4
Chions 4
Dallas 4
Dulles 4
East Providence 4
Ft. Washington 4
Totale 2.605
Nome #
Benefits and Harms of Lung Cancer Screening by Chest Computed Tomography: A Systematic Review and Meta-Analysis, file e27ce432-3568-2581-e053-d805fe0acbaa 352
The evolving paradigm of precision medicine in lung cancer, file e27ce432-feec-2581-e053-d805fe0acbaa 262
Erratum to: The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis (Scientific Reports, (2018), 8, 1, (13379), 10.1038/s41598-018-30780-4), file e27ce42d-ea5f-2581-e053-d805fe0acbaa 241
Multisciplinary management of patients with liver metastasis from colorectal cancer, file e27ce42d-c09f-2581-e053-d805fe0acbaa 210
Repositioning PARP inhibitors in the treatment of thoracic malignancies, file e27ce432-5f29-2581-e053-d805fe0acbaa 187
Italian survey on the clinical management of non-small cell lung cancer patients during the COVID-19 pandemic: A lesson for the second wave, file e27ce431-36e2-2581-e053-d805fe0acbaa 183
Five-year overall survival of pembrolizumab in advanced non-small cell lung cancer: another step from care to cure?, file e27ce42e-dc22-2581-e053-d805fe0acbaa 165
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy, file e27ce432-13ee-2581-e053-d805fe0acbaa 151
Potential Role of ANGPTL4 in the Cross Talk between Metabolism and Cancer through PPAR Signaling Pathway, file e27ce42d-bec6-2581-e053-d805fe0acbaa 138
A systematic review and meta-analysis of trials assessing PD-1/PD-L1 immune checkpoint inhibitors activity in pre-treated advanced stage malignant mesothelioma, file e27ce435-141e-2581-e053-d805fe0acbaa 138
Immune-Checkpoint Inhibitors Combinations in Metastatic NSCLC: New Options on the Horizon?, file e27ce431-6018-2581-e053-d805fe0acbaa 124
Immunotherapy in first line for extensive-stage small-cell lung cancer: another piece is going to fill the puzzle?, file e27ce42d-f0c1-2581-e053-d805fe0acbaa 122
PD-L1 expression as predictive biomarker in patients with NSCLC: A pooled analysis, file e27ce42d-c0a0-2581-e053-d805fe0acbaa 118
Second-Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological, and Molecular Aspects of Nintedanib, file e27ce42d-bec7-2581-e053-d805fe0acbaa 109
Stabilizing versus destabilizing the microtubules: A double-edge sword for an effective cancer treatment option?, file e27ce42d-bce9-2581-e053-d805fe0acbaa 107
New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: Do all roads lead to RAS?, file e27ce42d-becc-2581-e053-d805fe0acbaa 101
"Back to a false normality": New intriguing mechanisms of resistance to PARP inhibitors, file e27ce42d-bced-2581-e053-d805fe0acbaa 97
Immune checkpoint inhibitors in lung cancer: the holy grail has not yet been found…, file e27ce42d-bec9-2581-e053-d805fe0acbaa 89
Improving lung cancer outcomes through smoking cessation: The women against lung cancer in Europe (WALCE) experience, file e27ce430-743f-2581-e053-d805fe0acbaa 89
Circulating programmed death ligand-1 (cPD-L1) in non-small- cell lung cancer (NSCLC), file e27ce42d-bcf3-2581-e053-d805fe0acbaa 88
Descriptive Comparative Analysis of Patients With Cancer Referring to the Emergency Department of an Italian University Hospital Across the Severe Acute Respiratory Syndrome Coronavirus 2 Waves, file e27ce431-eea7-2581-e053-d805fe0acbaa 87
The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status, file e27ce42d-c0a1-2581-e053-d805fe0acbaa 83
Nintedanib in NSCLC: Evidence to date and place in therapy, file e27ce42d-c099-2581-e053-d805fe0acbaa 82
Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer, file e27ce431-768f-2581-e053-d805fe0acbaa 78
SARS-CoV-2 Infection in Cancer Patients: A Picture of an Italian Onco-Covid Unit, file e27ce430-3392-2581-e053-d805fe0acbaa 76
Treatment of advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines, file e27ce42f-1801-2581-e053-d805fe0acbaa 74
The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis, file e27ce42f-6924-2581-e053-d805fe0acbaa 71
Epidermal growth factor receptor exon 20 insertion variants in non-small cell lung cancer patients, file e27ce435-06a5-2581-e053-d805fe0acbaa 71
Is there any place for immune-checkpoint inhibitors in the treatment algorithm of fusion-driven non-small cell lung cancer?-a literature review, file e27ce431-4cdd-2581-e053-d805fe0acbaa 70
Exploring the immune-checkpoint inhibitors' efficacy/tolerability in special non-small cell lung cancer (NSCLC) populations: Focus on steroids and autoimmune disease, file e27ce432-6b1c-2581-e053-d805fe0acbaa 69
Optimizing the clinical management of EGFR-mutant advanced non-small cell lung cancer: a literature review, file 6a4f2d12-9d18-46e9-9cbe-17f2d1412540 67
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation, file e27ce431-1f27-2581-e053-d805fe0acbaa 66
Diagnosis and treatment of early and locally advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines, file e27ce42f-4c8c-2581-e053-d805fe0acbaa 65
Clinical and molecular features of epidermal growth factor receptor (Egfr) mutation positive non‐small‐cell lung cancer (nsclc) patients treated with tyrosine kinase inhibitors (tkis): Predictive and prognostic role of co‐mutations, file e27ce431-f183-2581-e053-d805fe0acbaa 57
First-line immune-chemotherapy combination: the right strategy to fight squamous non-small-cell lung cancer?., file e27ce430-5908-2581-e053-d805fe0acbaa 55
Targeting chimeras fusion proteins in non-small cell lung cancer: where are we going?, file e27ce431-4488-2581-e053-d805fe0acbaa 51
Real-world retrospective study of KRAS mutations in advanced nonsmall cell lung cancer in the era of immunotherapy, file 1757043c-dfd9-462f-aca4-6b3000d9189b 47
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%, file e27ce435-25e5-2581-e053-d805fe0acbaa 44
Immune-checkpoint inhibition in stage III unresectable NSCLC: Challenges and opportunities in the post-PACIFIC era, file e27ce431-d7d0-2581-e053-d805fe0acbaa 36
Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations, file e27ce430-eff4-2581-e053-d805fe0acbaa 24
Treatment of metastatic non-small cell lung cancer: 2018 guidelines of the Italian Association of Medical Oncology (AIOM), file e27ce431-50a6-2581-e053-d805fe0acbaa 18
Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations, file e27ce42d-d6ac-2581-e053-d805fe0acbaa 17
Detection of RAS mutations in circulating tumor DNA: a new weapon in an old war against colorectal cancer. A systematic review of literature and meta-analysis, file 3179112a-4408-48d0-8fe6-ca5eb646282f 16
First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status, file e27ce430-a2d1-2581-e053-d805fe0acbaa 16
KRAS inhibition in non–small cell lung cancer: Past failures, new findings and upcoming challenges, file e27ce430-1e22-2581-e053-d805fe0acbaa 15
Dealing with NSCLC EGFR mutation testing and treatment: a comprehensive review with an Italian real-world perspective, file e27ce431-9132-2581-e053-d805fe0acbaa 14
Short-Term Safety and Psychosocial Impact of the BNT162b2 mRNA COVID-19 Vaccine in Cancer Patients-An Italian Single-Center Experience, file 1c670a39-e041-4b2c-a8d4-b7e4f04c9729 13
Comparing T Cell Subsets in Broncho-Alveolar Lavage (BAL) and Peripheral Blood in Patients with Advanced Lung Cancer, file da5de55f-f3c4-4f0c-9ea1-6482648974b4 13
RET-MAP: An international multi-center study on clinicobiologic features and treatment response in patients with lung cancer harboring a RET fusion, file 42981468-93e3-4187-b7ab-199d8e1409a5 12
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes, file e27ce431-47ef-2581-e053-d805fe0acbaa 12
COVID-19 and Lung Cancer: A Comprehensive Overview from Outbreak to Recovery, file e27ce435-335d-2581-e053-d805fe0acbaa 11
Exploring the Potential of Non-Coding RNAs as Liquid Biopsy Biomarkers for Lung Cancer Screening: A Literature Review, file 0c345b25-573f-43d9-943c-474bbf82cb05 10
Upfront Management of ALK-Rearranged Metastatic Non-small Cell Lung Cancer: One Inhibitor Fits All?, file e27ce431-0429-2581-e053-d805fe0acbaa 9
Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients, file 287fb88b-fed5-483d-b718-73e5f88501cd 7
A strategy to overcome EGFR p.T790M cis p.L792F induced resistance to osimertinib, file 6b74d542-4ab6-49af-b772-c1cc9c061ecf 7
Targeted Therapies in Small Cell Lung Cancer: From Old Failures to Novel Therapeutic Strategies, file 9d49614e-3c64-4b37-92c0-bcfebac6bb13 6
Rare thoracic cancers: a comprehensive overview of diagnosis and management of small cell lung cancer, malignant pleural mesothelioma and thymic epithelial tumours, file 07a75a22-80ab-4b55-94cb-26300f231011 5
Rate and risk factors of recurrent immune checkpoint inhibitor-related pneumonitis in patients with lung cancer, file b81a9fb2-3c86-4b37-9445-794211404551 5
Autocrine 17-β-estradiol/estrogen receptor-α loop determines the response to immune-checkpoint inhibitors in non-small cell lung cancer, file 4fd1d643-3fe1-48cc-9a70-14974c325626 4
Deciphering Lung Adenocarcinoma Heterogeneity: An Overview of Pathological and Clinical Features of Rare Subtypes, file 8f2d78f8-d9ad-4a47-a9a7-27c03c22f02b 4
Should adjuvant treatment be offered to patients with stage IB non-small cell lung cancer?, file b655ac61-1b46-4734-b79b-69832f2388c5 3
The role of targeted therapy for gastrointestinal tumors, file e27ce42d-bcee-2581-e053-d805fe0acbaa 3
Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer?, file e27ce42d-bd52-2581-e053-d805fe0acbaa 3
Extracellular Vesicles As miRNA Nano-Shuttles: Dual Role in Tumor Progression, file e27ce42d-c09a-2581-e053-d805fe0acbaa 3
Monoclonal antibodies for the treatment of non-hematological tumors: a safety review, file e27ce42d-f1b2-2581-e053-d805fe0acbaa 3
Lung Cancer in Italy, file e27ce42f-00d2-2581-e053-d805fe0acbaa 3
Sotorasib in KRASp.G12C mutated advanced NSCLC: Real-world data from the Italian expanded access program, file 2411ef4a-6c8f-4b69-b231-243bf720e585 2
Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has Begun, file 7cd50f06-c41e-4c15-9b41-08d8f4530013 2
Pralsetinib in RET fusion-positive non-small-cell lung cancer: A real-world data (RWD) analysis from the Italian expanded access program (EAP), file d16be77e-0b3f-451e-9568-e22bb1376cb6 2
Niraparib plus Dostarlimab in Pleural Mesothelioma or Non-Small Cell Lung Cancer harboring HRR mutations: interim results of the UNITO-001 phase 2 prospective trial, file d7451cd4-5dc6-46ad-9c48-b5a99ddd90ca 2
Monoclonal antibodies for the treatment of non-haematological tumours: Update of an expanding scenario, file e27ce42d-bce6-2581-e053-d805fe0acbaa 2
The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?, file e27ce42d-bce7-2581-e053-d805fe0acbaa 2
Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis, file e27ce42d-bce8-2581-e053-d805fe0acbaa 2
Cardiotoxicity mechanisms of the combination of BRAF-inhibitors and MEK-inhibitors, file e27ce42d-bcec-2581-e053-d805fe0acbaa 2
Metastatic site location influences the diagnostic accuracy of ctDNA EGFR- mutation testing in NSCLC patients: a pooled analysis, file e27ce42d-bcf4-2581-e053-d805fe0acbaa 2
Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patients’ selection, file e27ce42d-bcf5-2581-e053-d805fe0acbaa 2
Looking for a new panacea in ALK-rearranged NSCLC: may be Ceritinib?, file e27ce42d-bd51-2581-e053-d805fe0acbaa 2
ALK and crizotinib: After the honeymoon...what else? Resistance mechanisms and new therapies to overcome it, file e27ce42d-bec5-2581-e053-d805fe0acbaa 2
Ramucirumab and its use in gastric cancer treatment, file e27ce42d-bec8-2581-e053-d805fe0acbaa 2
Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab, file e27ce42d-becb-2581-e053-d805fe0acbaa 2
Primary and metastatic brain cancer genomics and emerging biomarkers for immunomodulatory cancer treatment, file e27ce42d-becd-2581-e053-d805fe0acbaa 2
Prognostic and predictive biomarkers for targeted therapy in NSCLC: For whom the bell tolls?, file e27ce42d-bece-2581-e053-d805fe0acbaa 2
Adding chemotherapy to TKI: Can we improve first-line treatment for EGFR-mutated NSCLC patients?, file e27ce42d-becf-2581-e053-d805fe0acbaa 2
EGFR inhibition in NSCLC: New findings…. and opened questions?, file e27ce42d-bed2-2581-e053-d805fe0acbaa 2
The effects of enzalutamide and abiraterone on skeletal related events and bone radiological progression free survival in castration resistant prostate cancer patients: An indirect comparison of randomized controlled trials, file e27ce42d-c09b-2581-e053-d805fe0acbaa 2
The role of cMET in non-small cell lung cancer resistant to EGFR-Inhibitors: Did we really find the target?, file e27ce42d-c09c-2581-e053-d805fe0acbaa 2
Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects, file e27ce42d-c09e-2581-e053-d805fe0acbaa 2
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%, file e27ce434-99bf-2581-e053-d805fe0acbaa 2
The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies, file 10513e37-bc3b-4d03-b044-6c59b151d23c 1
Optimizing diagnosis and treatment of EGFR exon 20 insertions mutant NSCLC, file 97bf9931-1187-44af-a0a7-8c8818d6f4b3 1
Alectinib for the treatment of pretreated RET-rearranged advanced NSCLC: Results of the ETOP ALERT-lung trial, file de9bb73b-1b5d-4b2e-b805-cb7aa8d293d6 1
The role of microRNAs in driving EGFR-TKI resistance in NSCLC cell lines, file e27ce42d-a252-2581-e053-d805fe0acbaa 1
Analysis of Germline Gene Copy Number Variants of Patients with Sporadic Pancreatic Adenocarcinoma Reveals Specific Variations, file e27ce42d-bce5-2581-e053-d805fe0acbaa 1
Cancer and the microbiome: Potential applications as new tumor biomarker, file e27ce42d-bcf1-2581-e053-d805fe0acbaa 1
Anti-angiogenic drugs for second-line treatment of NSCLC patients: Just new pawns on the chessboard?, file e27ce42d-bcf2-2581-e053-d805fe0acbaa 1
Entrectinib: A potent new TRK, ROS1, and ALK inhibitor, file e27ce42d-bed0-2581-e053-d805fe0acbaa 1
Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors, file e27ce42d-bed1-2581-e053-d805fe0acbaa 1
What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis, file e27ce42d-c09d-2581-e053-d805fe0acbaa 1
Immunotherapy in non-small-cell lung cancer: a bridge between research and clinical practice, file e27ce42d-cc93-2581-e053-d805fe0acbaa 1
Totale 4.631
Categoria #
all - tutte 7.117
article - articoli 0
book - libri 0
conference - conferenze 1
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7.118


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019244 0 0 0 0 0 0 0 79 15 69 73 8
2019/2020450 8 6 7 21 7 13 29 75 104 66 63 51
2020/2021910 46 67 80 44 42 87 39 58 128 168 61 90
2021/20221.709 151 80 92 134 170 100 173 183 157 112 258 99
2022/2023949 94 58 202 135 70 63 63 61 76 58 44 25
2023/2024369 39 29 56 40 49 41 82 33 0 0 0 0
Totale 4.631